vimarsana.com

Latest Breaking News On - Eva haas - Page 1 : vimarsana.com

Eva Noblezada, Latinx retelling of The Taming of the Shrew, and more public art

Actress Eva Noblezada talks about her personal journey in theater. Plus, a new romance book does its own spin on Shakespeare. And, public art at a local university.

Marlene Kolling

Marlene (Haas) Kolling was born on May 29, 1942, to Joseph and Eva Haas. She was the 6th of 8 children born into the family. She grew up and attended school in Lefor, ND where her family had a farm. Marlene loved reading and going to dances. She met and married the love of her life, George F. Kolling, who was from Dickinson, ND. They were married on July 12, 1961, while George was in the Air Force. George and Marlene had raised three children; George who they called, Butch, Laurie and Neil. Their eldest son, Butch was born in Rapid City, SD while George was in the Air Force; Laurie and Neil were born in Dickinson, where they resided after George got out of the service. The family moved to Glendive, MT in 1975. In 1976, Marlene started work at the Burlington Northern Credit Union and was eventually the Manager of the Credit Union until she retired in 2004. After retiring, she and George moved to Bismarck, to be closer to Laurie and her children.

Exelixis, Inc : Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U S Patients Hospitalized with COVID-19

Published: Apr 23, 2021 LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group. “Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” commented Mike Wells, MD, a pulmonologist and Principal Investigator at the

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.